British Journal of Cancer (1999) 80, 1420–1426. doi:10.1038/sj.bjc.6690538 www.bjcancer.com
Published online 11 June 1999
Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo
S Hazama1, T Noma2, F Wang1, N Iizuka1, Y Ogura1, K Yoshimura1, E Inoguchi3, M Hakozaki3, K Hirose3, T Suzuki1 and M Oka1
- 1Departments of Surgery II, Yamaguchi University School of Medicine, 1144 Kogushi, Ube, Yamaguchi 755, Japan
- 2Departments of Biochemistry II, Yamaguchi University School of Medicine, 1144 Kogushi, Ube, Yamaguchi 755, Japan
- 3Biomedical Research Institute, Kureha Chemical Industry, 3-26-2 Hyakunin-cho, Shinjuku-ku Tokyo, 169, Japan
Received 8 September 1997; Revised 16 September 1998; Accepted 12 January 1999.
Top of pageAbstract
We examined the effect of interleukin-15 (IL-15) gene transfer into tumour cells on the host's anti-tumour response. In BALB/c mice IL-15 producing Meth-A cells (Meth-A/IL-15) underwent complete rejection, in a response characterized by massive infiltration of CD4+ T-cells and neutrophils. In contrast, Meth-A cells transfected with vector alone (Meth-A/Neo) grew rapidly. Moreover, rechallenged parental cells also were rejected in association with CD8+ T-cell infiltration. However, in nude mice there was no drastic difference between Meth-A/IL-15 and Meth-A/Neo cells. These results demonstrate that IL-15-secreting tumour cells can stimulate local and systemic T-cell-dependent immunity and therefore may have a potential role in cancer therapy.
Keywords:
IL-15, tumour immunity, vaccination, in vivo animal models, gene therapy
Top of pageReferences
- Andeson, D. M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, A., Giri, J. G., Copeland, N. G., Gilbert, D., Jenkins, N. A., Valentin, V., Shapiro, D. N., Morris, S. W., Park, L. S. & Cosman, D. (1995). Functional characterization of the human interleukin-15 receptor
chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 270: 29862–29869. | Article | PubMed | ISI | ChemPort | - Armitage, R. J., Macduff, B. M., Eisenman, J., Paxton, R. & Grabstein, K. H. (1995). IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154: 483–490. | PubMed | ISI | ChemPort |
- Bamford, R. N., Battiata, A. P. & Waldmann, T. A. (1996). IL-15: the role of translational regulation in their expression. J Leukocyte Biol 59: 476–480. | PubMed | ChemPort |
- Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K. & Caligiuri, M. A. (1994). Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180: 1395–1403. | Article | PubMed | ISI | ChemPort |
- Cavallo, F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Modesti, A. & Forni, G. (1992). Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149: 3627–3635. | PubMed | ISI | ChemPort |
- Colombo, M. P. & Forni, G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48–51. | Article | PubMed | ISI | ChemPort |
- Corbett, T. H., Griswold, D. P. Jr, Roberts, B. J., Peckham, J. C. & Schabel, F. M. Jr (1975). Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res 35: 2434–2439. | PubMed | ISI | ChemPort |
- DeLeo, A. B., Shiku, H., Takahashi, T., John, M. & Old, L. Y. (1977). Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and allo-antigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 146: 720–734. | Article | PubMed | ISI | ChemPort |
- Gamero, A. M., Ussery, D., Reintgen, D. S., Puleo, C. A. & Djeu, J. Y. (1995). Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 55: 4988–4994. | PubMed | ChemPort |
- Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D. & Anderson, D. (1994). Utilization of the
- and
-chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822–2830. | PubMed | ISI | ChemPort | - Giri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., DuBose, R., Cosman, D., Park, L. S. & Anderson, D. M. (1995). Identification and cloning of a novel IL-15 binding protein that is structurally related to the
chain of the IL-2 receptor. EMBO J 14: 3654–3663. | PubMed | ISI | ChemPort | - Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M. & Giri, J. G. (1994). Cloning of a T cell growth factor that interacts with the
-chain of the interleukin-2 receptor. Science 264: 965–968. | Article | PubMed | ISI | ChemPort | - Hirose, K., Hakozaki, M., Nyunoya, Y., Kobayashi, Y., matsushita, K., Takenouchi, T., Mikata, A., Mukaida, N. & Matsushima, K. (1995). Chemokine gene transfection into tumor cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 72: 708–713. | PubMed | ISI | ChemPort |
- Iizuka, N., Oka, M., Noma, T., Nakazawa, A., Hirose, K. & Suzuki, T. (1995). NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res 55: 652–657. | PubMed | ChemPort |
- Lebel-Binay, S., Laguerre, B., Quintin-Colonna, F., Conjeaud, H., Magazin, M., Miloux, B., Pecceu, F., Caput, D., Ferrara, P. & Fradelizi, D. (1995). Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 25: 2340–2348.
- Lewko, W. M., Smith, T. L., Bowman, D. J., Good, R. W. & Oldham, R. K. (1995). Interleukin-15 and the growth of tumor derived activated T cells. Cancer Biother 10: 13–20.
- Meazza, R., Gaggero, A., Neglia, F., Basso, S., Sforzini, S., Pereno, R., Azzarone, B. & Ferrini, A. (1997). Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides. Eur J Immunol 27: 1049–1054. | Article | PubMed | ISI | ChemPort |
- Mori, A., Suko, M., Kaminuma, O., Inoue, S., Ohmura, T., Nishizaki, Y., Nagahori, T., Asakura, Y., Hoshino, A., Okumura, Y., Sato, G., Ito, K. & Okudaira, H. (1996). IL-15 promotes cytokine production of human T helper cells. J Immunol 156: 2400–2405. | PubMed | ISI | ChemPort |
- Munger, W., DeJoy, S. Q., Jeyaseelan R, S. r., Torley, L. W., Grabstein, K. H., Eisenmann, J., Paxtox, R., Cox, R. T., Wick, M. M. & Kerwar, S. S. (1995). Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165: 289–293. | Article | PubMed | ISI | ChemPort |
- Nishimura, H., Washizu, J., Nakamura, N., Enomoto, A. & Yoshikai, Y. (1998). Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA. J Immunol 160: 936–942. | PubMed | ISI | ChemPort |
- Tokunaga, K., Taniguchi, H., Yoda, K., Shimizu, M. & Sakiyama, S. (1986). Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA. Nucleic Acids Res 14: 2829–2829. | PubMed | ISI | ChemPort |
- Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Mitchison, Pierrepoint, C. G., Raymond, R., Rowlatt, C., Stephens, T. C. & Wallace, J. (1988). UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia. Br J Cancer 58: 109–113. | PubMed |
- Wilkinson, P. C. & Liew, F. Y. (1995). Chemoattraction of human blood T lymphocytes by interleukin-15. J Exp Med 181: 1255–1259. | Article | PubMed | ISI | ChemPort |
- Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A. & Lotze, M. T. (1995). Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155: 1393–1403. | PubMed | ISI | ChemPort |